/EINPresswire.com/ -- MILFORD, MA--(Marketwired - May 04, 2016) - RenalGuard Solutions™, Inc., an innovative renal protection company, today announced that it will present its innovative RenalGuard System™ at a breakfast seminar and in its booth at SCAI 2016, the annual meeting of the Society for Cardiovascular Angiography and Interventions, May 4-7, 2016 in Orlando, Florida. More than 1500 clinicians and professionals are expected to attend this event.

RenalGuard® will be included as part of a sponsored breakfast session on Contrast-Induced Acute Kidney Injury (CK-AKI) on Thursday, May 5th at 6:45 AM. The event, Contrast-Induced Acute Kidney Injury: Focus on Hydration and Dye Saving, features some of the world's top CI-AKI experts discussing their research and experience around protecting patients from this damaging condition. Data from a number of clinical trials, utilizing a variety of different therapies will be discussed. The session is chaired by Roxana Mehran, MD, FSCAI, Mount Sinai Medical Center, New York. More information and registration details are available at http://akiatscai.com/.

A number of cardiology conferences have included late-breaking clinical trial data on potential methods to prevent CK-AKI in at-risk patients, including the AVERT trial, which was presented at SCAI, and the CARIN trial which was presented at the recent American College of Cardiology conference last month.

"The data from these trials confirms that the rate of at-risk patients developing CK-AKI during and after percutaneous coronary intervention (PCI) remains very high, and that preventing this is a major challenge," said Andrew Halpert, President, RenalGuard Solutions, Inc. "The inclusion of these trials as late breaking trials demonstrates the high level of interest in CI-AKI prevention. We look forward to discussing this at the seminar and conference, and to presenting data from recent clinical trials demonstrating that the use of RenalGuard Therapy® can significantly reduce this occurrence."

RenalGuard measures a patient's urine output and automatically infuses hydration fluid based on that urine output. The system is designed to induce high urine rates, which have been shown to protect the kidney from a range of insults. A number of clinical studies have demonstrated RenalGuard's ability to protect patients from AKI following catheterization procedures when compared to the standard of care, including: MYTHOS, which found RenalGuard to be superior to overnight hydration; REMEDIAL II, which found RenalGuard to be superior to sodium bicarbonate hydration; Protect-TAVI, which reported a significant reduction in post-procedural acute kidney injury (AKI) following transcatheter aortic valve replacement (TAVR) when using RenalGuard during the procedure, compared to standard therapy; and AKIGUARD, which showed significant improvement in long-term outcomes when using RenalGuard vs. standard therapy.

About RenalGuard Solutions, Inc.

RenalGuard Solutions, Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. Our lead product, RenalGuard, is designed to protect patients from acute kidney injury (AKI), including contrast-induced AKI. Two investigator-sponsored studies in Europe have demonstrated RenalGuard's effectiveness at preventing CI-AKI in at-risk patients. RenalGuard is CE-marked and is being sold in Europe and certain countries around the world via a network of distributors. The CIN-RG RenalGuard pivotal study is underway in the U.S. to support a planned Premarket Approval filing with the U.S. Food and Drug Administration. For further information, please visit the website at www.RenalGuard.com.

Contact:
Gregory Mann
CFO
508-541-8800
gmann@renalguard.com